Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.60 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3996984 | 0.88 | SMN1; SMN2 (0.59) | MTNR1AMTNR1BSMN1; SMN2CA12CA1 | |
| SCHEMBL2224069 | 0.86 | CA12 (0.73) | MTNR1AMTNR1BSMN1; SMN2CA12CA1 | |
| SCHEMBL23997386 | 0.85 | ALDH1A1 (0.58) | MTNR1AMTNR1BSMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL30336782 | 0.85 | ALDH1A1 (0.58) | MTNR1AMTNR1BSMN1; SMN2ALDH1A1HSD17B10 | |
| Water SCHEMBL11279885 | 0.85 | CA12 (0.71) | MTNR1AMTNR1BSMN1; SMN2CA12CA1 | |
| SCHEMBL5723848 | 0.84 | MTNR1A (0.84) | MTNR1AMTNR1BSMN1; SMN2MAPTKDM4E | |
| SCHEMBL146690 | 0.82 | CA1 (0.69) | CA12CA1CA2CA9MAPT | |
| SCHEMBL13076594 | 0.81 | LMNA (0.69) | SMN1; SMN2CA1CA2KDM4EALDH1A1 | |
| SCHEMBL5723908 | 0.81 | KDM4E (0.69) | MTNR1AMTNR1BSMN1; SMN2CA12CA1 | |
| SCHEMBL31467954 | 0.80 | MTNR1A (0.62) | MTNR1AMTNR1BSMN1; SMN2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10155259-B2 | FSH receptor antagonists | MERCK SHARP & DOHME B.V. (NL) | 2018-12-18 | — | — | US | disclosed |
| EP-2763986-B1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (NL) | 2017-06-07 | — | — | EP | disclosed |
| EP-2763986-B1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (NL) | 2017-06-07 | — | — | EP | disclosed |
| US-20150329545-A1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME B.V. (NL) | 2015-11-19 | — | — | US | disclosed |
| US-20150329545-A1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME B.V. (NL) | 2015-11-19 | — | — | US | disclosed |
| US-20150329545-A1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME B.V. (NL) | 2015-11-19 | — | — | US | disclosed |
| US-9127007-B2 | FSH receptor antagonists | MERCK SHARP & DOHME B.V. (NL) | 2015-09-08 | — | — | US | disclosed |
| US-9127007-B2 | FSH receptor antagonists | MERCK SHARP & DOHME B.V. (NL) | 2015-09-08 | — | — | US | disclosed |
| US-9127007-B2 | FSH receptor antagonists | MERCK SHARP & DOHME B.V. (NL) | 2015-09-08 | — | — | US | disclosed |
| US-20140350043-A1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME B.V. (NL) | 2014-11-27 | — | — | US | disclosed |
| US-20140350043-A1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME B.V. (NL) | 2014-11-27 | — | — | US | disclosed |
| US-20140350043-A1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME B.V. (NL) | 2014-11-27 | — | — | US | disclosed |
| EP-2763986-A1 | FSH RECEPTOR ANTAGONISTS | Merck Sharp & Dohme B.V. (NL) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013041458-A1 | FSH RECEPTOR ANTAGONISTS | MSD OSS B.V. (NL) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350043-A1 | FSH RECEPTOR ANTAGONISTS | FSHR, GNRHR, LHCGR | MTNR1A 74/4885MTNR1B 86/4885SMN1; SMN2 2827/4885 |
| US-10155259-B2 | FSH receptor antagonists | FSHR, GNRHR, LHCGR | MTNR1A 85/4885MTNR1B 93/4885SMN1; SMN2 2911/4885 |
| US-20150329545-A1 | FSH RECEPTOR ANTAGONISTS | FSHR, GNRHR, LHCGR | MTNR1A 85/4885MTNR1B 93/4885SMN1; SMN2 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.